# Yueyin Pan

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/yueyin-pan/

## Facts

| Field | Value |
| --- | --- |
| Citations | 9,256 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 40 |
| i10-index | 103 |
| Last Known Institution | University of Science and Technology of China |
| OpenAlex ID | https://openalex.org/A5002727383 |
| ORCID iD | 0000-0003-0532-5368 |
| Works | 234 |

## Researcher papers

- [Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial](https://scholariq.org/papers/pembrolizumab-in-combination-with-gemcitabine-and-cisplatin-compared-with/)
- [Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study](https://scholariq.org/papers/camrelizumab-versus-investigator-s-choice-of-chemotherapy-as-second-line-therapy/)
- [Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial](https://scholariq.org/papers/camrelizumab-plus-carboplatin-and-pemetrexed-versus-chemotherapy-alone-in/)
- [Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial](https://scholariq.org/papers/sintilimab-versus-placebo-in-combination-with-chemotherapy-as-first-line/)
- [Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer](https://scholariq.org/papers/effect-of-first-line-serplulimab-vs-placebo-added-to-chemotherapy-on-survival-in/)
- [Multiplexed Nanomaterial-Based Sensor Array for Detection of COVID-19 in Exhaled Breath](https://scholariq.org/papers/multiplexed-nanomaterial-based-sensor-array-for-detection-of-covid-19-in-exhaled/)
- [Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer](https://scholariq.org/papers/sintilimab-plus-chemotherapy-for-unresectable-gastric-or-gastroesophageal/)
- [Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial](https://scholariq.org/papers/camrelizumab-plus-carboplatin-and-paclitaxel-as-first-line-treatment-for/)
- [Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study](https://scholariq.org/papers/tislelizumab-plus-chemotherapy-versus-placebo-plus-chemotherapy-as-first-line/)
- [Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial](https://scholariq.org/papers/tucidinostat-plus-exemestane-for-postmenopausal-patients-with-advanced-hormone/)
- [Treatment With Niraparib Maintenance Therapy in Patients With Newly Diagnosed Advanced Ovarian Cancer](https://scholariq.org/papers/treatment-with-niraparib-maintenance-therapy-in-patients-with-newly-diagnosed/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)

## Researcher university

- [University of Science and Technology of China](https://scholariq.org/institutions/university-of-science-and-technology-of-china/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.